About Adrestia
Adrestia is a Healthcare company based in Babraham (United Kingdom) founded in 2018, and was acquired by Insmed in July 2023. Pharmaceutical drugs for multiple therapeutic areas are manufactured. Its chief executive, as recorded, is Will Lewis. Adrestia offers products and services including Potatoes and Grain Marketing. Its focus areas include Traditional Pharmaceuticals. Its legal entity is Maine Potato Growers, Inc.
Company details
Adrestia was founded in 2018 and is based in Babraham, United Kingdom. Operations are centered on the manufacturing of drugs across various therapeutic areas within the pharmaceutical sector. Focus is placed on producing medications to address diverse medical needs. The company is led by CEO Will Lewis, with activities conducted from its UK location to support global health applications.
- Headquarters Babraham, United Kingdom
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website adrestia.com
- Social LinkedIn X
- Acquired by Insmed (Jul 2023)
- Legal Name Maine Potato Growers, Inc
Products & Services of Adrestia
Adrestia offers a comprehensive portfolio of products and services, including Potatoes and Grain Marketing.
Potatoes are farmed and sold for food and industrial purposes.
Grains are promoted and distributed from various farms.
Funding Insights of Adrestia
- Total Rounds 1
- Investors Count 2
All 1 funding rounds of Adrestia with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
3 investors in total: 3 institutional.
Investors in Adrestia
Adrestia has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Insmed, GSK and Ahren Innovation Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment in deep technology and science is facilitated. | 2017 | ahreninnovationcapital.com | ||
Developer of pharmaceuticals and vaccines for various therapeutic areas | 1715 | gsk.com | Brentford, United Kingdom | |
Developer of small molecule inhibitors for rare lung diseases | 1999 | insmed.com | Bridgewater, United States |
Investor details for Adrestia
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Adrestia
21 people are tracked at Adrestia (7 in leadership, 14 in team).
| Name | Role | Group |
|---|---|---|
Will Lewis | CEO | Leadership |
John Perry | Vice President of Human Genetics | Leadership |
Dr. Yaron Galanty | Co-Founder and VP research/ Head of research | Leadership |
Jane Whitrow | Interim Chief Operations Officer | Leadership |
Jennifer Millian | Vice President US Operations | Leadership |
Robert Johnson | Chief Executive Officer | Leadership |
James O. | Senior Director, Head of Chemistry | Leadership |
Flavius Alecsa | Scientist | Team |
Pantelitsa Protopapa, PhD | Research Scientist | Team |
Ana Camila Barros-Morter | Research Scientist | Team |
Catherine Klapholz | Senior Scientist | Team |
Walfred Tang | Principal Scientist | Team |
Caitriona Topping | Research Scientist | Team |
Adams George | Research Scientist | Team |
Zygimante Tarnauskaite | Research Scientist | Team |
Evdokia Paza | Scientist | Team |
Callum W. | Senior Scientist | Team |
Matthew Cook | Research Scientist | Team |
Eugene Gardner | Principal Scientist | Team |
Verena Zyka | Research Scientist | Team |
1 more people are available in the full profile.
Complete people profiles for Adrestia
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Adrestia
3 dated milestones of Adrestia across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Adrestia is founded.
- Funding First funding round.
- Exit Acquired by Insmed.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Adrestia
Adrestia was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Adrestia is headquartered in Babraham, United Kingdom. It is registered at Babraham, Cambridgeshire, United Kingdom.
Will Lewis is the CEO of Adrestia, as recorded in our data.
Adrestia was founded in 2018 and is based in Babraham, United Kingdom. Operations are centered on the manufacturing of drugs across various therapeutic areas within the pharmaceutical sector. Focus is placed on producing medications to address diverse medical needs. The company is led by CEO Will Lewis, with activities conducted from its UK location to support global health applications.
Adrestia offers Potatoes and Grain Marketing.
Adrestia has 3 investors. Key investors include Insmed, GSK, and Ahren Innovation Capital.
Adrestia operates through Maine Potato Growers, Inc.
Yes. Adrestia was acquired by Insmed in July 2023.